Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising new drug may offer safer option for duchenne boys

NCT ID NCT05185622

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 29 times

Summary

This study tested a drug called vamorolone in 54 boys with Duchenne muscular dystrophy (DMD), a muscle-weakening disease. The goal was to see if it is safe and can help control the disease with fewer side effects than standard steroids. Boys aged 2 to under 4 and 7 to under 18 took the drug for 12 weeks, and researchers monitored their health and muscle function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Alberta's Children Hospital

    Calgary, Alberta, AB T3B 6A8, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, V6H 3N1, Canada

  • Children's Hospital of Eastern Ontario

    Ottawa, Ontario, K1H 8L1, Canada

  • Montreal Childrens Hospital

    Montreal, H4A 3J1, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, M5G 1X8, Canada

Conditions

Explore the condition pages connected to this study.